Actinium Ac 225 dotatate

DB23632InvestigationalSmall molecule

Actinium Ac 225 dotatate is a biologic drug. Actinium Ac 225 dotatate is under investigation in clinical trial NCT07150806 (RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma).

Mechanism: Pharmacologically active on Somatostatin receptor type 2 and Somatostatin receptor
Curator reviewed
Also known as: 225Ac-DOTA-TATE · 225Ac-DOTATATE · Actinium Ac-225 dotatate
Code names: RYZ-101

Resolves to

Compound

UNIISP9ZNW6WAK

Targets

P30874SSTR2

What you can answer from here — as of June 27, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Actinium Ac 225 dotatate, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account